Myasthenia Gravis Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Myasthenia Gravis stocks.

Recent Signals

Date Stock Signal Type
2021-04-16 AKTX Crossed Above 200 DMA Bullish
2021-04-16 AKTX NR7 Range Contraction
2021-04-16 AKTX NR7-2 Range Contraction
2021-04-16 AKTX Narrow Range Bar Range Contraction
2021-04-16 AKTX Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-04-16 AKTX Calm After Storm Range Contraction
2021-04-16 ARGX 20 DMA Resistance Bearish
2021-04-16 ARGX 200 DMA Support Bullish
2021-04-16 ARGX 1,2,3 Retracement Bearish Bearish Swing Setup
2021-04-16 ARGX Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-04-16 IMVT 20 DMA Resistance Bearish

Recent News for Myasthenia Gravis Stocks

Date Stock Title
Apr 18 IMVT IMVT Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Immunovant, Inc. Investors of Class Action and Lead Plaintiff Deadline: April 20, 2021
Apr 16 IMVT SHAREHOLDER ALERT: Holzer & Holzer Encourages Immunovant Investors With Significant Losses to Contact the Firm
Apr 16 IMVT IMVT Tuesday Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Immunovant, Inc. Investors of Class Action and Lead Plaintiff Deadline: April 20, 2021
Apr 16 IMVT TUESDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Apr 16 ALXN Dow Jones Today Sets Pace As Futures Rise; Caterpillar Eyes Buy Point; Progygny, Lattice Semi Head For S&P 400
Apr 16 ALXN FTC clears AstraZeneca's acquisition of Alexion
Apr 16 ALXN AstraZeneca Cleared by FTC to Acquire Alexion
Apr 15 IMVT APRIL 20 DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses to Contact the Firm
Apr 15 IMVT The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (IMVT)
Apr 15 IMVT IMVT Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Immunovant, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: April 20, 2021
Apr 15 IMVT TUESDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Apr 14 IMVT TUESDAY DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Apr 14 IMVT IMVT Approaching Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Immunovant, Inc. Investors of Class Action and Lead Plaintiff Deadline: April 20, 2021
Apr 14 IMVT Immunovant, Inc. Technology Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm
Apr 13 IMVT SHAREHOLDER DEADLINE THIS MONTH: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses to Contact the Firm
Apr 13 AKTX Circling Back On Akari Therapeutics
Apr 13 IMVT 7-DAY DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Apr 13 IMVT IMVT Looming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Immunovant, Inc. Investors of Class Action and Lead Plaintiff Deadline: April 20, 2021
Apr 13 GTBP IRhythm extends losses as more downgrades pile up, Aphria cut to neutral after earnings miss; and more in today’s analyst action
Apr 13 AKTX 25 Stocks Moving in Tuesday's Pre-Market Session
Related Industries: Biotechnology

Myasthenia gravis (MG) is a long-term neuromuscular disease that leads to varying degrees of skeletal muscle weakness. The most commonly affected muscles are those of the eyes, face, and swallowing. It can result in double vision, drooping eyelids, trouble talking, and trouble walking. Onset can be sudden. Those affected often have a large thymus or develop a thymoma.Myasthenia gravis is an autoimmune disease which results from antibodies that block or destroy nicotinic acetylcholine receptors at the junction between the nerve and muscle. This prevents nerve impulses from triggering muscle contractions. Rarely, an inherited genetic defect in the neuromuscular junction results in a similar condition known as congenital myasthenia. Babies of mothers with myasthenia may have symptoms during their first few months of life, known as neonatal myasthenia. Diagnosis can be supported by blood tests for specific antibodies, the edrophonium test, or a nerve conduction study.Myasthenia gravis is generally treated with medications known as acetylcholinesterase inhibitors such as neostigmine and pyridostigmine. Immunosuppressants, such as prednisone or azathioprine, may also be used. The surgical removal of the thymus may improve symptoms in certain cases. Plasmapheresis and high dose intravenous immunoglobulin may be used during sudden flares of the condition. If the breathing muscles become significantly weak, mechanical ventilation may be required.MG affects 50 to 200 per million people. It is newly diagnosed in three to 30 per million people each year. Diagnosis is becoming more common due to increased awareness. It most commonly occurs in women under the age of 40 and in men over the age of 60. It is uncommon in children. With treatment, most of those affected lead relatively normal lives and have a normal life expectancy. The word is from the Greek mys "muscle" and astheneia "weakness", and the Latin: gravis "serious".

More about Myasthenia Gravis
Browse All Tags